CAMP elevation down-regulates β3 integrin and focal adhesion kinase and inhibits leptin-induced migration of MDA-MB-231 breast cancer cells

BioResearch Open Access

Volumn 1, Issue 6, 2012, Pages 324-332

  Spina, Annamaria ^a   Di Maiolo, Francesca ^a   Esposito, Antonietta ^a   Sapio, Luigi ^a   Chiosi, Emilio ^a   Sorvillo, Luca ^a   Naviglio, Silvio ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

breast cancer cells; cAMP; leptin; migration; novel anticancer therapies

Indexed keywords

BETA3 INTEGRIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FOCAL ADHESION KINASE; FORSKOLIN; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE 3; STAT3 PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CELL ADHESION; CELL ASSAY; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

EID: 84901001741     PISSN: None     EISSN: 21647860     Source Type: Journal    
DOI: 10.1089/biores.2012.0270     Document Type: Article

References (53)

1. American Cancer Society. Cancer Facts and Figures 2011. Atlanta, GA: American Cancer Society; 2011.
2. Veronesi U, Boyle P, Goldhirsch A, Orecchia R, Viale G. Breast cancer. Lancet. 2005;365:1727-1741.
3. Van't Veer LJ, Weigelt B. Road map to metastasis. Nat Med. 2003;9:999-1000.
4. Polacheck WJ, Zervantonakis IK, Kamm RD. Tumor cell migration in complex microenvironments. Cell Mol Life Sci. 2012 Aug 25 [Epub ahead of print]; DOI: 10.1007/s00018- 012-1115-1.
5. Rakha EA, Chan S. Metastatic triple-negative breast cancer. Clin Oncol. 2011;23:587-600.
6. Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125: 627-636.
7. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372:425-432.
8. Jeong JK, Szabo G, Raso GM, et al. Deletion of prolyl carboxypeptidase attenuates the metabolic effects of dietinduced obesity. Am J Physiol Endocrinol Metab. 2012; 302:E1502-1510.
9. Schwartz MW, Baskin DG, Kaiyala KJ, Woods SC. Model for the regulation of energy balance and adiposity by the central nervous system. Am J Clin Nutr. 1999;69:584-596.
10. Garofalo C, Surmacz E. Leptin and cancer. J Cell Physiol. 2006;207:12-22.
11. Yin N, Wang D, Zhang H, et al. Molecular mechanisms involved in the growth stimulation of breast cancer cells by leptin. Cancer Res. 2004;64:5870-5875.
12. Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res. 2004;10:4325-4331.
13. Jardé T, Caldefie-Chezet F, Damez M, et al. Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncol Rep. 2008;19: 905-911.
14. Revillion F, Charlier M, Lhotellier V, et al. Messenger RNA expression of leptin and leptin receptors and their prognostic value in 322 human primary breast cancers. Clin Cancer Res. 2006;12(7 Pt 1):2088-2094.
15. Frankenberry KA, Skinner H, Somasundar P, et al. Leptin receptor expression and cell signaling in breast cancer. Int J Oncol. 2006;28:985-993.
16. Ray A, Nkhata KJ, Cleary MP. Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol. 2007;30:1499-1509.
17. Knight BB, Oprea-Ilies GM, Nagalingam A, et al. Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr Relat Cancer. 2011;18:413-428.
18. Ando S, Catalano S. The multifactorial role of leptin in driving the breast cancer microenvironment. Nat Rev Endocrinol. 2011;8:263-275.
19. Ray A, Cleary MP. Leptin as a potential therapeutic target for breast cancer prevention and treatment. Expert Opin Ther Targets. 2010;14:443-451.
20. Naviglio S, Di Gesto D, Romano M, et al. Leptin enhances growth inhibition by cAMP elevating agents through apoptosis of MDA-MB-231 breast cancer cells. Cancer Biol Ther. 2009;8:1183-1190.
21. Naviglio S, Di Gesto D, Illiano F, et al. Leptin potentiates antiproliferative action of cAMP elevation via protein kinase A down-regulation in breast cancer cells. J Cell Physiol. 2010; 225:801-809.
22. Schwede F, Maronde E, Genieser H, Jastorff B. Cyclic nucleotide analogs as biochemical tools and prospective drugs. Pharmacol Ther. 2000;87:199-226.
23. Vitale G, Dicitore A, Mari D, Cavagnini F. A new therapeutic strategy against cancer: cAMP elevating drugs and leptin. Cancer Biol Ther. 2009;8:1190-1196.
24. Dittmer A, Vetter M, Schunke D, et al. Parathyroid hormonerelated protein regulates tumor-relevant genes in breast cancer cells. J Biol Chem. 2006;281:14563-14572.
25. Chiosi E, Spina A, Sorrentino A, et al. Change in TNF-alpha receptor expression is a relevant event in doxorubicininduced H9c2 cardiomyocyte cell death. J Interferon Cytokine Res. 2007;27:589-597.
26. Naviglio S, SpinaA,Chiosi E, et al. Inorganic phosphate inhibits growth of human osteosarcoma U2OS cells via adenylate cyclase/ cAMP pathway. J Cell Biochem. 2006;98:1584-1596.
27. Du J, Sun C, Hu Z, et al. Lysophosphatidic acid induces MDA-MB-231 breast cancer cellsmigration through activation of PI3K/PAK1/ERK signaling. PLoS One. 2010;5:e15940.
28. Kim SH, Nagalingam A, Saxena NK, et al. Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3. Carcinogenesis. 2010;32:359-367.
29. Chen L, Zhang JJ, Huang XY. cAMP inhibits cell migration by interfering with Rac-induced lamellipodium formation. J Biol Chem. 2008;283:13799-13805.
30. Li DM, Feng YM. Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets. Breast Cancer Res Treat. 2011;128:7-21.
31. Golubovskaya VM, Cance W. Focal adhesion kinase and p53 signal transduction pathways in cancer. Front Biosci. 2010;15: 901-912.
32. Luo M, Guan JL. Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis. Cancer Lett. 2010;289:127-139.
33. Chioni AM, Shao D, Grose R, Djamgoz MB. Protein kinase A and regulation of neonatal Nav1.5 expression in human breast cancer cells: activity-dependent positive feedback and cellular migration. Int J Biochem Cell Biol. 2010;42:346-358.
34. Hansen C, Howlin J, Tengholm A, et al. Wnt-5a-induced phosphorylation of DARPP-32 inhibits breast cancer cell migration in a CREB-dependent manner. J Biol Chem. 2009;284:27533-27543.
35. McKenzie AJ, Campbell SL, Howe AK. Protein kinase A activity and anchoring are required for ovarian cancer cell migration and invasion. PLoS One. 2011;6:e26552.
36. Fan CF, Mao XY, Wang EH. Elevated p-CREB-2 (ser 245) expression is potentially associated with carcinogenesis and development of breast carcinoma. Mol Med Rep. 2012;5: 357-362.
37. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000;351(Pt 1):95-105.
38. Enserink JM, Christensen AE, de Rooij J, et al. A novel Epacspecific cAMP analogue demonstrates independent regulation of Rap1 and ERK. Nat Cell Biol. 2002;4:901-906.
39. Naviglio S, Di Gesto D, Borrelli V, et al. Novel molecular mechanisms by inorganic phosphate in osteosarcoma U2OS cells. Front Biosci. 2011;E3:1249-1258.
40. Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol. 2010;28:3366-3379.
41. Reddy KB. Triple-negative breast cancers: an updated review on treatment options. Curr Oncol. 2011;18:173-179.
42. Otvos L Jr, Surmacz E. Targeting the leptin receptor: a potential new mode of treatment for breast cancer. Exp Rev Anticancer Ther. 2011;11:1147-1150.
43. Baum O, Hlushchuk R, Forster A, et al. Increased invasive potential and up-regulation of MMP-2 in MDA-MB-231 breast cancer cells expressing the beta3 integrin subunit. Int J Oncol. 2007;30:325-332.
44. Liu H, Radisky DC, Yang D, et al. MYC suppresses cancer metastasis by direct transcriptional silencing of av and b3 integrin subunits. Nat Cell Biol. 2012;14:567-574.
45. Nasulewicz-Goldeman A, Uszczyń ska B, Szczaurska-Nowak K, Wietrzyk J. siRNA-mediated silencing of integrin b3 expression inhibits the metastatic potential of B16 melanoma cells. Oncol Rep. 2012;28:1567-1573.
46. Golubovskaya VM, Conway-Dorsey K, Edmiston SN, et al. FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer. 2009;125:1735-1738.
47. Theocharis SE, Klijanienko JT, Padoy E, et al. Focal adhesion kinase (FAK) immunocytochemical expression in breast ductal invasive carcinoma (DIC): correlation with clinicopathological parameters and tumor proliferative capacity. Med Sci Monit. 2009;15:BR221-BR226.
48. Agochiya M, Brunton VG, Owens DW, et al. Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells. Oncogene. 1999;18:5646-5653.
49. Santen RJ, Song RX, McPherson R, et al. The role of mitogenactivated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol. 2002;80:239-256.
50. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:103-119.
51. Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs. 2005;16:601-607.
52. Germain D, Frank DA. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res. 2007; 13:5665-5669.
53. Johnston PA, Grandis Jr. STAT3 signaling: anticancer strategies and challenges. Mol Interv. 2011;11:18-26.